How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
|Articles|August 3, 2018
Mini Quiz: Borderline Personality Disorder
Author(s)Lois W. Choi-kain, MD
Listen
0:00 / 0:00
Key Takeaways
- Option C reflects that personality disorders, while clinically challenging, are treatable and should not be categorically labeled as untreatable.
- Clinician perceptions of “treatment resistance” can promote therapeutic nihilism and hinder sustained engagement, especially when countertransference is unrecognized.
Do personality disorders get a bad rap? Take the quiz and learn more.
Advertisement
The correct answer is C.
Clinicians often see patients with personality disorders as treatment resistant-and, in some cases, untreatable. While it is true that patients with personality disorders may be challenging to treat, they are treatable.
For more on this topic, see
Advertisement
Related to this article
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Don't miss out on these CME articles! Test your knowledge here.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5